Drug Profile
Brain cancer vaccine - Immune Response
Alternative Names: IR 850Latest Information Update: 09 Nov 2004
Price :
$50
*
At a glance
- Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 09 Sep 2004 Immune Response Corporation has signed a licensing transfer agreement with NovaRx covering rights in-licensed from the Sidney Kimmel Cancer Center
- 31 Dec 2003 Discontinued - Phase-I for Brain cancer in USA (Intradermal)
- 25 Jun 2002 This vaccine is still in active development